Wikisage, the free encyclopedia of the second generation, is digital heritage
Bezafibrate: Difference between revisions
Jump to navigation
Jump to search
(grammar) |
(→ATC: template) |
||
| Line 23: | Line 23: | ||
<references/> | <references/> | ||
{{Wikidata|Q577387}} | |||
[[Category:Hepatotoxic substances]] | [[Category:Hepatotoxic substances]] | ||
Revision as of 17:08, 14 December 2015
Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases. This fibrate reduces triglyceride and rises HDL-cholesterol[1][2]
ursodeoxycholic acid and bezafibrate are under study in the treatment of biliar cirrhosis (See Figure in gallery).
Links
Ginseng, green tea or fibrate: valid options for nonalcoholic steatohepatitis prevention?
ATC
Lipid modifying agents
- ↑ How Does Bezafibrate Affect the Plasma HDL Cholesterol Levels?
- ↑ Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes.
- ↑ Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis
- ↑ Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis
- ↑ http://www.whocc.no/atc_ddd_index/?code=C10AB02
